Rebuzzi, S.E.; Rescigno, P.; Catalano, F.; Mollica, V.; Vogl, U.M.; Marandino, L.; Massari, F.; Pereira Mestre, R.; Zanardi, E.; Signori, A.;
et al. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers 2022, 14, 1245.
https://doi.org/10.3390/cancers14051245
AMA Style
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A,
et al. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers. 2022; 14(5):1245.
https://doi.org/10.3390/cancers14051245
Chicago/Turabian Style
Rebuzzi, Sara Elena, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori,
and et al. 2022. "Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives" Cancers 14, no. 5: 1245.
https://doi.org/10.3390/cancers14051245
APA Style
Rebuzzi, S. E., Rescigno, P., Catalano, F., Mollica, V., Vogl, U. M., Marandino, L., Massari, F., Pereira Mestre, R., Zanardi, E., Signori, A., Buti, S., Bauckneht, M., Gillessen, S., Banna, G. L., & Fornarini, G.
(2022). Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers, 14(5), 1245.
https://doi.org/10.3390/cancers14051245